Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1282-1284

  Korba, Brent E ^a   Boyd, Malcolm R ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXYPROPOXY)GUANINE; 9 [2 (PHOSPHONOMETHOXY)ETHOXY]ADENINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; 9 [3 HYDROXY 2 (HYDROXYMETHYL)PROPOXY]GUANINE; ACICLOVIR; FAMCICLOVIR; PENCICLOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG EFFECT; DRUG POTENCY; DRUG SPECIFICITY; HEPATITIS B; HEPATITIS B VIRUS; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0029916081     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1282     Document Type: Article

References (26)

1. Alexander, G. J. M., E. A. Fagan, J. E. Hegarty, A. L. W. F. Eddleston, and R. Williams. 1987. Controlled clinical trial of acyclovir in chronic hepatitis B virus infection. J. Med Virol. 21:81-87.
2. Boyd, M. R., S. Safrin, and E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance, pattern. Antiviral Chem. Chemother. 4(Suppl. 1):3-11.
3. Darlison, S. J., D. L. Earnshaw, and R. A. Vere Hodge. Personal communication.
4. Dienstag, J. L., R. P. Perillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1994. Double-blind, randomized, three-month, dose-ranging trial of lamivudine for chronic hepatitis B. J. Hepatol. 20:412A.
5. Duckworth, D. M., M. R. Harnden, R. M. Perkins, and D. N. Planterose. 1991. Antiviral 9-[2-(phosphonomethoxy)alkoxy]purines. Antiviral Chem. Chemother 2:229-241.
6. Earnshaw, D. L., T. H. Bacon, S. J. Darlison, K. Edmonds, R. M. Perkins, and R. A. Vere Hodge. 1992 Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:2747-2757.
7. Erlt, P., W. Snowden, D. Lowe, W. Miller, P. Collins, and E. Littler. 1995. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antiviral Chem. Chemother. 6:89-97.
8. Harnden, M. R., P. G. Wyatt, M. R. Boyd, and D. Sutton. 1990. Synthesis and antiviral activity of 9-alkoxypurines. 1 9-(3-Hydroxypropoxy)- and 9-[3-hydroxy-2-(hydroxymethyl)propoxy]purines. J. Med. Chem. 33:187-196.
9. Ilsley, D. D., S.-H. Lee, W. H. Miller, and R. D. Kuchta. 1995. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 34:2504-2510
10. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture system to evaluate nueleoside analogues for activity against hepatitis B virus replication. Antiviral Res. 19:55-70.
11. Korba, B. E., and G. Milman. 1991 A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 15:217-228.
12. Kruger, M., H. L. Tillmann, C. Trautwein, U. Bode, K. Oldhafer, K. H. W. Boker, R. Pichlmmayr, and M. P. Manns. 1994. Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir, p. 134. In Proceedings of the American Association for the Study of Liver Disease. 45th Annual Meeting.
13. Lee, B., W. Luo, S. Suzuki, M. J. Robins, and D. L. J. Tyrrell. 1989. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 33:336-339.
14. Main, J., J. L. Brown, P. Karayiannis, P. Georgiou, M. Boyd, W. Prince, and H. Thomas. 1994. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Hepatol. 21(Suppl 1):S32.
15. Mok, S. S., T. Shaw, and S. Locarnini. 1995. Preferential inhibition of human hepatitis B virus (HBV) DNA polymerase by the (R)-enantiomer of penciclovir triphosphate, abstr. H66, p. 191. In Abstracts of the 35th Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Perkins, R. M., A. Immelmann, L. Elphik, D. M. Duckworth, M. R. Harnden, M. D. Kenig, D. Planterose, and A. G. Brown. 1992. Antiviral activity of 9-{2-(phosphonomethoxy)ethoxy}purines against HIV, FIV, and visna virus. Antiviral Res. 17(Suppl 1):33 (Abstract 29)
17. Pue, M. A., S. K. Pratt, A. J. Fairless, S. Fowles, J. Laroche, P. Georgiou, and W. Prince. 1994. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500, and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33:119-127.
18. Saltzman, R., R. Jurewicz, and R. Boon. 1994. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. 38:2454-2457.
19. Schinazi, R. F., G. Gosselin, A. Faraj, B. E. Korba, D. C. Liotta, C. K. Chu, C. Mathe, J.-L. Imbach, and J.-P. Sommadossi. 1994 Pure nucleoside enantiomers of β-2′.3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother. 38:2172-2174.
20. Schlam, S. W., R. A. Heytink, H. R. Van Buuren, and R. A. De Man. 1986 Acyclovir, oral, intravenous, and combined with interferon for chronic HBeAg-positive hepatitis. J. Hepatol. 3(Suppl. 2):S137-S141.
21. Sells, M. A., A. Z. Zelent, M. Shvartsman, and G. Acs. 1988. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
22. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother 38:719-723
23. Sutton, D., M. R. Boyd, and K. Tsiquaye. 1993. Evaluation of penciclovir and its oral form, famciclovir against a chronic hepatitis infection in ducks, abstr. 1594, p. 410. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
24. Tsiquaye, K. N., M. J. Slomka, and M. Maung. 1994. Oral famciclovir against duck hepatitis B virus replication in hepatic and non-hepatic tissues of ducklings infected in ovo. J. Med. Virol. 42:306-310.
25. Vere Hodge, R. A. 1993 Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 4:67-84.
26. Zoulim, F., E. Dannaoui, and C. Trepo. 1995. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription, abstr. H13, p. 182. In Program and abstracts of the 35th Interscience Conterence on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C